Catalent completes acquisition of gene therapy leader Paragon Bioservices for $1.2 billion
Catalent announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, a leading viral vector development and manufacturing partner for gene therapies. Paragon has GMP manufacturing projects underway with more than half of the top 40 leading gene therapy developers worldwide. May 20, 2019